Effects of Sarcopenia, Myosteatosis, and the Prognostic Nutritional Index on Survival in Stage 2 and 3 Gastric Cancer Patients

We aimed to evaluate the relationship between sarcopenia, myosteatosis, and systemic inflammatory response biomarkers and their prognostic role in stage 2 and 3 gastric cancer patients. This study included 84 patients with stage 2 or 3 gastric cancer who underwent a gastrectomy. Computed tomography...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition and cancer 2023, Vol.75 (1), p.368-375
Main Authors: Bir Yucel, Kadriye, Karabork Kilic, Atiye Cenay, Sutcuoglu, Osman, Yazıcı, Ozan, Aydos, Uguray, Kilic, Koray, Özdemir, Nuriye
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Computed tomography
Gastrectomy
Gastrectomy - adverse effects
Gastric cancer
Humans
Inflammation
Inflammatory response
Multivariate analysis
Muscle, Skeletal - pathology
Muscles
Nutrition Assessment
Prognosis
Retrospective Studies
Sarcopenia
Sarcopenia - epidemiology
Sarcopenia - etiology
Skeletal muscle
Stomach Neoplasms - complications
Stomach Neoplasms - surgery
Survival
Vertebrae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the relationship between sarcopenia, myosteatosis, and systemic inflammatory response biomarkers and their prognostic role in stage 2 and 3 gastric cancer patients. This study included 84 patients with stage 2 or 3 gastric cancer who underwent a gastrectomy. Computed tomography scans were used to determine the skeletal muscle index (SMI) at the third lumbar vertebra level for sarcopenia and myosteatosis. Based on the Asian Working Group of Sarcopenia (AWGS2019) criteria, the sarcopenia incidence was 36.9% and that of myosteatosis 46.4%. Univariate analysis showed that sarcopenia (48 vs. 14 mo, p 
ISSN:0163-5581
1532-7914
DOI:10.1080/01635581.2022.2121845